Summary The investigations reported in this paper aim to exploit tumour necrosis factor (TNF)-induced vascular changes in an attempt to increase the tumour uptake of specific monoclonal antibody. The vascular permeability to monoclonal antibody of a human tumour xenograft increased 2.6-fold by 1 h post injection of 2.5 x 103 U of TNF, although this effect was lost by 3 h. The normal tissues also demonstrated increased vascular permeability to IgG, but to a lesser exent. Liver permeability increased 1.5-fold at I h but returned to the control value by 6 h. Lung permeability increased 1.4-fold at 1 h post injection and returned to normal by 3 h. Muscle values were not significantly increased compared with controls. The blood activity was cleared more quickly in the TNF-treated mice (ti = 101 h, compared with 121 h in control mice). This was probably due to the increased vascular permeability in normal organs of treated mice. At I day and 3 days post injection, the tumour uptake of the specific, but not the control, antibody was significantly increased by 25% and 29% respectively. This resulted in an increase in the area under the tumour activity curve, and therefore tumour radiation dose, of 25% in treated compared with control mice. In addition, a consequence of the faster blood clearance of the isotope in the TNF-treated mice was a reduction in the area under the blood activity curve of 12%, thereby reducing systemic toxicity. The increase in vascular permeability to IgG following TNF injection resulted in both specific and control antibodies having improved access to the tumour antigens, and a transient increase in uptake was observed. Only in the case of the specific antibody was the increase maintained, since this antibody binds to the available antigenic sites, whereas the control antibody was cleared from the tumour without binding. No evidence of tumour necrosis was observed at the TNF doses given, nor was there any toxicity to the mice.
Vascular parameters such as blood flow, vascular permeability and vascular volume are serious obstacles limiting delivery of cytotoxic agents, including radiolabelled monoclonal antibodies, to tumours. Antibody access to tumour cells may be limited by the tumour vasculature, with its abnormal vessels and poor blood flow, and by regions of high interstitial pressure (Jain and Baxter, 1988; Jain, 1991) .
Tumour vascular permeability and blood flow have been shown to correlate well with the uptake of monoclonal antibody in two different human tumour xenografts, the tumour having twice the vascular permeability, resulting in a 5-fold increase in antibody uptake (Sands et al., 1988) . However, few attempts have been made to alter tumour vascular parameters. Bomber et al. (1986) showed that the ,-blocker propranolol increases tumour perfusion and 67Ga uptake in a mouse sarcoma. Smyth et al. (1987) have shown, in a xenograft model, that both non-selective and cardioselective Padrenergic blocking agents increase the tumour-blood and tumour-liver uptake ratios of '"I-labelled monoclonal antibody. Attard et al. (1991) used the corticosteroid dexamethasone to reduce tumour interstitial pressure and thereby increase the tumour-background ratios in patients being investigated by immunoscintigraphy. In one patient, two metastatic deposits which were not visible without dexamethasone administration became visible after dexamethasone. Tumour vessels differ from normal vessels, particularly in lacking sufficient smooth muscle to dilate or constrict in response to drugs which have these effects on normal blood vessels. By their selective action on normal blood vessels, vasoactive drugs can change the tumour-normal tissue perfusion ratio (Chan et al., 1984) .
The cytokine interleukin 2 (IL-2) has been shown to increase vascular permeability in normal organs, either alone (Rosenstein et al., 1986) or in combination with lymphokineactivated killer cells (Ettinghausen et al., 1988) . Tumour necrosis factor (TNF) is another cytokine which has been shown to increase endothelial permeability directly, as measured in endothelial cell monolayers (Royall et al., 1989) . In vivo, TNF is known to be a mediator of the inflammatory response, and can lead to diffuse intravascular coagulation with consequent changes in vascular permeability. This damage to tumour vasculature induces ischaemia and haemorrhagic necrosis of the tumour within 24 h of administration, both in animal models (Palladino et al., 1987; van de Wiel et al., 1989) and in a patient (Robertson et al., 1989) . This phenomenon was first exploited by Coley (1891), who treated sarcoma patients by injecting bacterial cultures containing Streptococcus erysipelatis, and noted tumour regressions, some complete, in many patients. The principal active constituent of Coley's toxins was undoubtedly lipopolysaccharide (LPS), which is a potent inducer of TNF. Endotoxic shock is associated with acute vascular endothelial injury resulting in oedema (Brunson et al., 1955) . Administration of TNF to rats, in doses similar to those produced endogenously in response to endotoxin, produces many of the symptoms of LPS toxaemia, including hypotension, pulmonary inflammation and haemorrhage (Tracey et al., 1986) . Pulmonary vascular leakage has also been induced in sheep by injection of TNF (Horvath et al., 1988) . The barrier function of the endothelium has been shown to be altered directly by TNF (Sato et al., 1986 ). Aicher et al. (1990 have detected changes in capillary permeability to gadolinium-conjugated albumin in Meth A sarcomas in mice following TNF administration by means of contrast-enhanced magnetic resonance imaging. van de Wiel et al. (1989) suggested that the broad interference of tumour blood supply was the major cause of necrosis of Meth A sarcomas in mice, since TNF did not affect the Meth A cells in vitro. TNF has been shown to increase vascular permeability in vivo immediately after injection (Kallinowski et al., 1989), and to affect the functional and structural vascular volume in solid murine tumours (van de Wiel et al., 1990) . Since poor vasculature is one of the factors limiting antibody uptake in tumours (Jain, 1991) , if tumour vascular permeability could be increased by the administration of TNF, this would facilitate antibody access to tumour cell antigens. The investigations reported in this paper aim to exploit these vascular changes in an attempt to increase the tumour uptake of specific monoclonal antibody.
Materials and methods

Tumour model
The animals used in these studies were female nude mice of mixed genetic background. They were bred under specific pathogen-free conditions at the Imperial Cancer Research Fund Animal Breeding Unit, South Mimms, Herts, UK, and subsequently housed in sterile filter-top cages with sterile bedding, and maintained on irradiated diet and autoclaved, acidified water (pH 2.8).
The human tumour cell line HT29 was established in cell culture in 1964 from a primary tumour in a female patient with adenocarcinoma of the colon (Fogh and Trempe, 1975) . Tumour cells were cultured in RPMI-1640 medium containing 100 U ml-' penicillin and 1I00 Lg ml-' streptomycin, supplemented with 10% fetal calf serum (FCS) (Gibco, Paisley, UK) at 37°C in a humidified atmosphere of 5% carbon dioxide in air. Tumours were established in the right flanks of the mice by subcutaneous injection of 5 x 106 cells in 100 pl of tissue culture medium. Animals were used for experiment 3-4 weeks later, when the tumours were 6-8 mm in diameter.
Antibodies AUAI Monoclonal antibody AUA1, of the IgGI subclass, was raised by immunising Balb/c mice with a human colon carcinoma cell line (Arklie, 1981) . AUA1 recognises a Mr 35 000 cell-surface glycoprotein, which is coded for by a gene on chromosome 2, and which is only expressed in epithelial cells (Spurr et al., 1986) . The antibody reacts with a wide range of tumours of epithelial origin such as breast, lung, ovarian and gastrointestinal cancers, as well as with proliferating epithelial cells in tissues such as normal colon, but not with any non-epithelial tissues or tumours (Arklie, 1981; Spurr et al., 1986) . AUA1 was used as the specific antibody for HT29 tumours.
HMFGJ This monoclonal antibody, also IgGI, was raised in Balb/c mice using delipidated human milk fat globule as immunogen . The antibody is directed against a core protein determinant of a high molecular weight glycoprotein (Mr>400000) normally produced by the lactating human mammary epithelial cell (Burchell et al., 1987) , but also found on some carcinomas, such as those of breast, ovary and lung, but not with tumours of mesenchymal tissue . HMFG1 does not bind to HT29 cells and was used as the irrelevant control antibody.
Radiolabelling
Antibodies were labelled with '25I or '3'I (IMS 30 and IBS 30 respectively; Amersham International, Amersham, Bucks, UK) to a specific activity of approximately 2 uCi uLg' using the lodo-Gen method (Fraker and Speck, 1978) .
Tumour necrosis factor Recombinant human tumour necrosis factor (specific activity 2.27 x 10 U mg-') was supplied by Asahi Chemical Industry, Tokyo, Japan. Vials containing I05 U (44 pg) in 1 ml of water were stored at -20°C until immediately before use. (1985) , who replaced 51Cr labelling of erythrocytes in vitro with radiolabelling in vivo using 99!Tc (Pavel et al., 1977) .
Groups of tumour-bearing mice were given i. The haematocrit (the percentage red cell volume in the blood) was measured for several mice and found to agree with the published value for mice of 40% (Green, 1979) , which was therefore used in all calculations. It has been found, however, that the haematocrit in tissues is less than that in the systemic circulation (O'Connor and Bale, 1984) . Since, in the present study, vascular permeability is compared within the model in tumour and normal organs with and without TNF administration, then if the haematocrit were different from the systemic value this would result in a systematic error in both measurements, as it is unlikely that TNF administration alters the haematocrit.
The efficiency of red cell labelling was estimated by injecting a group of mice with the same reagents at the same time intervals as the experimental animals, and killing them by exsanguination 1 h post injection of radioisotopes. The blood was then centrifuged for 15 min at 2000 r.p.m. in a bench centrifuge to isolate the red cells, which were washed twice with phosphate-buffered saline (PBS). The 125I and 9"mTc activities in the erythrocytes and plasma were measured. Biodistribution Nude mice bearing s.c. HT29 tumours were given a mixture of 5 pg each of '113-labelled AUA1 and '251-labelled HMFG1 antibodies i.v. In half the mice 2.5 x 103 U of TNF was combined with the injected antibody. Groups of four treated and control mice were dissected at times between 2 h and 6 days after antibody administration.
Statistical analysis
The statistical significance of the difference between means was determined using the Student's t-test. A P-value <0.05 was considered to be significant. by 6 h. Lung permeability increased 1.4-fold at 1 h post injection (P< 0.02) and returned to normal by 3 h. Muscle values did not increase significantly from controls. Tables I and II show the uptake of co-injected specific (AUAI) and control (HMFGl) antibodies, with or without the inclusion of 2.5 x 103 U of TNF, in mice bearing s.c. HT29 xenografts. The blood activity was cleared more quickly in the TNF-treated mice (for AUAl and HMFG1, respectively, ti = 101 h and 101 h in TNF-treated mice compared with 121 h and 115 h in control mice). Although there are few time points used to calculate these values, since the same result is observed for both antibodies, it may be a genuine effect caused by increased vascular permeability in normal organs of treated mice. Two hours post injection, the tumour uptake of both antibodies was increased 2-fold, however this was not significant owing to the large errorn points. The tumour uptake of the control antib was within the range of the normal organs at , studied, while the tumour uptake of the spe (Table I ) was higher than all normal organs I injection. At 1 day and 3 days post injectiol uptake of the specific, but not the control, significantly increased by 25% and 29%, resp pared with that in untreated mice. This results in the area under the tumour activity curve, tumour radiation dose, of 25% in treated c control, mice, as shown in Figure 3 . In addi quence of the faster blood clearance of the TNF-treated mice is a reduction in the area ur activity curve of 12%, thereby reducing syste
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Discussion
The increase in tumour vascular permeability fi injection (Figure 2) (Table II) of tumour vascular permeability in relation to antibody all time points uptake has been demonstrated by Sands et al. (1988) (Wong and Goeddel, 1988 umans than in nude mice, targeting an antibody-TNF fusion protein to the tumour should allow lower doses to be given systemically to achieve the same tumour dose. Hoogenboom et al. (1991) have produced a hybridoma capable of secreting an antibody-TNF fusion protein which retains the biological activities of both constituent molecules in vitro. This type of fusion protein may be capable of specifically increasing tumour vascular permeability without the increase in normal tissue permeability observed in the studies reported in this paper. A recombinant fusion protein of a single-chain Fv region and IL-2 which retains the biological properties of each constituent protein has been produced (Savage et al., 1993) . This method should also be suitable for TNF-sFv fusions, since the gene for human TNF has been cloned and expressed in Escherichia coli (Shirai et al., 1985) .
